HPBCD will be dosed in patients with diabetic kidney disease in Q2 2025

Today's cyclodextrin, drug development, ,

Today’s cyclodextrin:
ZyVersa Therapeutics Inc.‘ Cholesterol Efflux Mediator VAR 200 (HPBCD) will be dosed in patients with diabetic kidney disease in Q2 2025.

The first patient is expected to be treated in a phase 2a clinical trial in patients with DKD by the end of June of 2025. The intent of the study is to obtain renal patient proof-of-concept for VAR 200 prior to initiating a larger phase 2a/b for VAR 200’s lead indication, FSGS. The DKD study will evaluate VAR 200’s safety and efficacy (% change in proteinuria from baseline to week 12) in eight patients with type 2 diabetes who have diabetic kidney disease. This data will provide insights for designing the subsequent phase 2a/b FSGS study. The DKD study will be conducted at two clinical research sites.

I cannot wait to see how this goes!
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress :: ZyVersa Therapeutics, Inc.

Pediatric Orally Disintegrating Tablets (ODTs) with Enhanced Palatability Based on Propranolol HCl Coground with Hydroxypropyl-β-Cyclodextrin

Today's cyclodextrin, , ,

Today’s cyclodextrin is a nice case study of creating Pediatric Orally Disintegrating Tablets with Enhanced Palatability.

This work by Università degli Studi di Firenze and University of Milan aimed to exploit cyclodextrin complexation by cogrinding to develop orally disintegrating tablets (ODTs) endowed with reliable dosing accuracy, good palatability and safety, ease of swallowability, and ultimately better compliance for both pediatric patients and caregivers.

Such a new dosage form of propranolol with HPBCD could represent a valid alternative to the common extemporaneous preparations, overcoming the lack of solid formulations of propranolol intended for pediatric use.

Marzia Cirri, Paola Mura, Francesca Maestrelli, Simona Benedetti and Susanna Buratti

Pediatric Orally Disintegrating Tablets (ODTs) with Enhanced Palatability Based on Propranolol HCl Coground with Hydroxypropyl-β-Cyclodextrin

Supersaturated Drug Delivery System of Oxyberberine Based on Cyclodextrin Nanoaggregates: Preparation, Characterization, and in vivo Application

drug discovery, Today's cyclodextrin,

Today’s cyclodextrin is a fascinating practical application of CDs – how can we create a supersatured drug delivery system (SDDS)?

In this paper, Oxyberberine (OBB) – hydroxypropyl-β-CD SDDS was prepared using the ultrasonic-solvent evaporation method.

The oral relative bioavailability of OBB-HP-β-CD SDDS was also 16 times enhanced compared to that of the raw material. Finally, an in vivo pharmacodynamic assay showed that the anti-hyperuricemic potency of OBB-HP-β-CD SDDS was approximately 5– 10 times higher than that of OBB raw material.

Supersaturated drug delivery system of oxyberberine | IJN (dovepress.com)

CarboHyde blog, Supersaturated Drug Delivery System of Oxyberberine Based on Cyclodextrin Nanoaggregates: Preparation, Characterization, and in vivo Application

Evaluation of the performance of Hydroxypropyl-β-cyclodextrin for the consolidation of vegetable-tanned leather artifacts

Today's cyclodextrin

Today’s cyclodextrin:
Hydroxypropyl-β-cyclodextrin for the consolidation of vegetable-tanned leather artifacts

The fragility and weakness of historical, archaeological, and heritage leather artifacts in museums, and libraries due to unsuitable environmental conditions are significant challenges.

Vegetable-tanned leather samples were treated with different concentrations of Hydroxypropyl Beta Cyclodextrin and subjected to artificial heat aging.

Results showed that Hydroxypropyl Beta Cyclodextrin at 1% and 2% concentrations improved chemical stability, surface morphology, color retention, and mechanical properties of the leather samples.

Evaluation of the performance of Hydroxypropyl-β-cyclodextrin for the consolidation of vegetable-tanned leather artifacts | Heritage Science | Full Text (springeropen.com)

Insulin formulation and methods of using same in preterm infants

drug development, Today's cyclodextrin,

Today’s cyclodextrin is an excellent example of using CDs (in this particular case, HPBCD) in peptide/protein formulations. ELGAN Pharma‘s patent concerns combining insulin, cyclodextrins, and other components, where the role of the CD is stabilization and cryopreservation.

As we see more examples of CD-protein combinations in research and clinical practice, I am convinced that this use will shape future applications.

Espacenet – US2024165205A1